SCI
RVMD icon

S&CO Inc’s Revolution Medicines RVMD Stock Holding History

S&CO Inc’s Portfolio RVMD Stock Details RVMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.4M Hold
34,171
– – 0.37% 59
2026
Q1 		$3.32M Hold
34,171
– – 0.21% 90
2025
Q4 		$2.72M Buy
34,171
+12,000
+54% +$787K 0.17% 101
2025
Q3 		$1.03M Buy
22,171
+8,000
+56% +$313K 0.06% 141
2025
Q2 		$521K Buy
14,171
+5,000
+55% +$192K 0.03% 169
2025
Q1 		$324K Buy
+9,171
New +$372K 0.02% 188

Other funds holding RVMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
DGM
Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

S&CO Inc's RVMD Position: Q2 2026 in Review

S&CO Inc held its Revolution Medicines (RVMD) position steady in Q2 2026 at 34,171 shares worth $6.4M. The position accounts for 0.37% of the portfolio, ranked #59.

S&CO Inc first reported a position in RVMD in Q1 2025 and has held it in 6 quarters since. 691 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

  • S&CO Inc held 34,171 shares of Revolution Medicines worth $6.4M as of Q2 2026.
  • S&CO Inc left its Revolution Medicines share count unchanged in Q2 2026.
  • Revolution Medicines made up 0.37% of S&CO Inc's portfolio in Q2 2026, its #59 holding.
  • S&CO Inc first reported a position in Revolution Medicines in Q1 2025 and has held it in 6 quarters since.
  • 691 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on S&CO Inc's 13F filing for Q2 2026, filed 6 Aug 2026.